Aequus Pharmaceuticals Inc (AQS) - Net Assets
Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has net assets worth CA$-6.89 Million CAD (≈ $-4.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$196.16K ≈ $141.90K USD) and total liabilities (CA$7.09 Million ≈ $5.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aequus Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-6.89 Million |
| % of Total Assets | -3514.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1224.65% |
| 10-Year Change | -602.47% |
| Growth Volatility | 337.53 |
Aequus Pharmaceuticals Inc - Net Assets Trend (2013–2024)
This chart illustrates how Aequus Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore AQS total asset value for the complete picture of this company's asset base.
Annual Net Assets for Aequus Pharmaceuticals Inc (2013–2024)
The table below shows the annual net assets of Aequus Pharmaceuticals Inc from 2013 to 2024. For live valuation and market cap data, see market value of Aequus Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-6.45 Million ≈ $-4.67 Million |
-50.33% |
| 2023-12-31 | CA$-4.29 Million ≈ $-3.11 Million |
-211.14% |
| 2022-12-31 | CA$-1.38 Million ≈ $-998.30K |
-177.14% |
| 2021-12-31 | CA$1.79 Million ≈ $1.29 Million |
+211.71% |
| 2020-12-31 | CA$573.95K ≈ $415.19K |
+165.44% |
| 2019-12-31 | CA$-877.09K ≈ $-634.48K |
-152.16% |
| 2018-12-31 | CA$1.68 Million ≈ $1.22 Million |
-27.04% |
| 2017-12-31 | CA$2.31 Million ≈ $1.67 Million |
+82.12% |
| 2016-12-31 | CA$1.27 Million ≈ $915.58K |
-1.48% |
| 2015-12-31 | CA$1.28 Million ≈ $929.30K |
-56.03% |
| 2014-12-31 | CA$2.92 Million ≈ $2.11 Million |
+941.14% |
| 2013-12-31 | CA$280.60K ≈ $202.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aequus Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3323263400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$28.41 Million | % |
| Total Equity | CA$-6.45 Million | 100.00% |
Aequus Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CML Microsystems Plc
LSE:CML
|
$479.85K |
|
Foncière 7 investissement Société Anonyme
PA:LEBL
|
$480.00K |
|
Craven House Capital PLC
LSE:CRV
|
$482.95K |
|
Upsellon Brands Holdings Ltd
TA:CHR
|
$485.04K |
|
Time Out Group plc
LSE:TMO
|
$476.93K |
|
Gelion PLC
LSE:GELN
|
$474.39K |
|
Time Finance PLC
LSE:TIME
|
$474.07K |
|
TCTM Kids IT Education Inc.
NASDAQ:VSA
|
$472.81K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aequus Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,293,844 to -6,454,992, a change of -2,161,148.
- Net loss of 2,177,662 reduced equity.
- Other comprehensive income decreased equity by 4,399,500.
- Other factors increased equity by 4,416,014.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.18 Million | -33.74% |
| Other Comprehensive Income | CA$-4.40 Million | -68.16% |
| Other Changes | CA$4.42 Million | +68.41% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Aequus Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CA$0.01 | CA$0.01 | x |
| 2014-12-31 | CA$0.12 | CA$0.01 | x |
| 2015-12-31 | CA$0.04 | CA$0.01 | x |
| 2016-12-31 | CA$0.03 | CA$0.01 | x |
| 2017-12-31 | CA$0.03 | CA$0.01 | x |
| 2018-12-31 | CA$0.02 | CA$0.01 | x |
| 2019-12-31 | CA$-0.01 | CA$0.01 | x |
| 2020-12-31 | CA$0.01 | CA$0.01 | x |
| 2021-12-31 | CA$0.01 | CA$0.01 | x |
| 2022-12-31 | CA$-0.01 | CA$0.01 | x |
| 2023-12-31 | CA$-0.03 | CA$0.01 | x |
| 2024-12-31 | CA$-0.05 | CA$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aequus Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -372.74%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-170.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -580.65% | 0.00% | 0.00x | 1.20x | CA$-1.66 Million |
| 2014 | -82.54% | 0.00% | 0.00x | 1.25x | CA$-2.70 Million |
| 2015 | -390.10% | 0.00% | 0.00x | 1.89x | CA$-5.14 Million |
| 2016 | -380.19% | -685.84% | 0.35x | 1.59x | CA$-4.94 Million |
| 2017 | -168.43% | -340.74% | 0.43x | 1.16x | CA$-4.11 Million |
| 2018 | -166.73% | -198.81% | 0.71x | 1.19x | CA$-2.97 Million |
| 2019 | 0.00% | -190.26% | 0.98x | 0.00x | CA$-3.02 Million |
| 2020 | -182.13% | -40.32% | 0.83x | 5.46x | CA$-1.10 Million |
| 2021 | -101.15% | -66.66% | 0.62x | 2.43x | CA$-1.99 Million |
| 2022 | 0.00% | -232.65% | 0.82x | 0.00x | CA$-3.07 Million |
| 2023 | 0.00% | -1163.11% | 0.23x | 0.00x | CA$-2.54 Million |
| 2024 | 0.00% | -372.74% | 0.73x | 0.00x | CA$-1.53 Million |
Industry Comparison
This section compares Aequus Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $822,629,963
- Average return on equity (ROE) among peers: -45.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aequus Pharmaceuticals Inc (AQS) | CA$-6.89 Million | -580.65% | N/A | $479.73K |
| Aurora Cannabis Inc (ACB) | $601.87 Million | -11.52% | 0.39x | $193.63 Million |
| Amotiv Limited (AOV) | $915.11 Million | 1.59% | 0.43x | $553.67 Million |
| Avicanna Inc (AVCN) | $841.07K | -309.08% | 1.52x | $13.17 Million |
| Avant Brands Inc (AVNT) | $-490.96K | 0.00% | 0.00x | $4.13 Million |
| Bausch Health Companies Inc (BHC) | $5.23 Billion | -16.55% | 4.34x | $2.06 Billion |
| CanadaBis Capital Inc (CANB) | $150.00K | 0.00% | 0.00x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $550.08 Million | -25.79% | 1.50x | $12.59 Million |
| Cipher Pharmaceuticals Inc (CPH) | $80.52 Million | 25.31% | 0.07x | $326.62 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $22.27 Million | -71.36% | 0.11x | $148.65 Million |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more